Abstract
OBJECTIVE: This study was designed to evaluate the immunogenicity, safety, and tolerability of a monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in children aged 6 to 23 months who had different gestational ages (GAs) at birth. METHODS: The study involved 105 children: 35 preterm subjects with a GA of
Original language | English |
---|---|
Journal | Pediatrics |
Volume | 127 |
Issue number | 5 |
DOIs | |
Publication status | Published - May 2011 |
Keywords
- A/H1N1 influenza vaccine
- Adjuvants
- MF59
- Pandemic influenza
- Preterm infants
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health